

Stephen R Saklad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5353955/publications.pdf>

Version: 2024-02-01

31
papers

1,234
citations

567144

15
h-index

552653

26
g-index

33
all docs

33
docs citations

33
times ranked

1118
citing authors

#	ARTICLE	IF	CITATIONS
1	Abuse and Misuse of Pregabalin and Gabapentin. <i>Drugs</i> , 2017, 77, 403-426.	4.9	295
2	Effects of smoking on fluphenazine clearance in psychiatric inpatients. <i>Biological Psychiatry</i> , 1985, 20, 329-332.	0.7	110
3	Clinical Pharmacokinetics of the Depot Antipsychotics. <i>Clinical Pharmacokinetics</i> , 1985, 10, 315-333.	1.6	106
4	Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. <i>Psychopharmacology</i> , 1986, 90, 468-70.	1.5	105
5	Effects of Carbamazepine on Plasma Haloperidol Levels. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 106-109.	0.7	88
6	Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, 10, 163-177.	1.4	73
7	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS Drugs</i> , 2021, 35, 39-59.	2.7	67
8	“Meta-guidelines” for the management of patients with schizophrenia. <i>CNS Spectrums</i> , 2013, 18, 150-162.	0.7	61
9	Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. <i>Pharmaceutical Research</i> , 1990, 07, 347-351.	1.7	60
10	Haloperidol and Reduced Haloperidol Plasma Levels in Selected Schizophrenic Patients. <i>Journal of Clinical Psychopharmacology</i> , 1984, 4, 138-142.	0.7	57
11	Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. <i>Psychiatry Research</i> , 1989, 30, 45-52.	1.7	45
12	Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, 193-202.	2.5	28
13	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. <i>Substance Abuse: Research and Treatment</i> , 2019, 13, 117822181984420.	0.5	19
14	Practical considerations for managing breakthrough psychosis and symptomatic worsening in patients with schizophrenia on long-acting injectable antipsychotics. <i>CNS Spectrums</i> , 2019, 24, 354-370.	0.7	17
15	Pimavanserin: A Novel Drug Approved to Treat Parkinson's Disease Psychosis. <i>Innovations in Clinical Neuroscience</i> , 2018, 15, 16-22.	0.1	17
16	Clinical Pharmacists' Impact on Prescribing in an Acute Adult Psychiatric Facility. <i>Drug Intelligence & Clinical Pharmacy</i> , 1984, 18, 632-634.	0.4	15
17	Failure of Tolterodine to Treat Clozapine-Induced Nocturnal Enuresis. <i>Annals of Pharmacotherapy</i> , 2001, 35, 867-869.	0.9	15
18	Very high dose loxapine in refractory schizophrenic patients. <i>American Journal of Psychiatry</i> , 1981, 138, 1212-1214.	4.0	10

#	ARTICLE	IF	CITATIONS
19	Revisiting Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	10
20	Alternative Drug Therapies for Mania: A Literature Review. <i>Drug Intelligence & Clinical Pharmacy</i> , 1984, 18, 577-589.	0.4	8
21	Lorazepam for the treatment of psychotic agitation. <i>American Journal of Psychiatry</i> , 1986, 143, 1195b-1196.	4.0	7
22	A Loading-Dose Strategy for Converting From Oral to Depot Haloperidol. <i>Psychiatric Services</i> , 1993, 44, 1155-1161.	1.1	7
23	A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. <i>Clinical Schizophrenia and Related Psychoses</i> , 2016, , .	1.4	4
24	Graphic representation of pharmacology: Development of an alternative model. <i>Mental Health Clinician</i> , 2017, 7, 201-206.	0.5	4
25	Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic. <i>CNS Spectrums</i> , 2022, 27, 230-230.	0.7	2
26	Dr. Ereshefsky and Associates Reply. <i>American Journal of Psychiatry</i> , 1982, 139, 701-a-702.	4.0	1
27	Bipolar Affective Disorders. , 1992, , 1127-1143.		1
28	Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia. <i>Mental Health Clinician</i> , 2015, 5, 149-161.	0.5	1
29	CAN FORMULATION TECHNOLOGY SPEED DRUG DEVELOPMENT AND IMPROVE THERAPEUTIC PROFILES FOR ANTIPSYCHOTICS?. <i>Schizophrenia Research</i> , 2008, 102, 44.	1.1	0
30	Monitoring for Antipsychotic Metabolic Effects in an Inpatient Setting. <i>Mental Health Clinician</i> , 2011, 1, 10-12.	0.5	0
31	Editorial: Metabolic effects and antipsychotics. <i>Mental Health Clinician</i> , 2011, 1, 1-2.	0.5	0